CA2751215A1 - Cell lines expressing cftr and methods of using them - Google Patents

Cell lines expressing cftr and methods of using them Download PDF

Info

Publication number
CA2751215A1
CA2751215A1 CA2751215A CA2751215A CA2751215A1 CA 2751215 A1 CA2751215 A1 CA 2751215A1 CA 2751215 A CA2751215 A CA 2751215A CA 2751215 A CA2751215 A CA 2751215A CA 2751215 A1 CA2751215 A1 CA 2751215A1
Authority
CA
Canada
Prior art keywords
cftr
cell
cells
intron
deletion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2751215A
Other languages
English (en)
French (fr)
Inventor
Kambiz Shekdar
Jessica Langer
Srinivasan P. Venkatachalan
Dennis J. Sawchuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromocell Corp
Original Assignee
Chromocell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromocell Corp filed Critical Chromocell Corp
Publication of CA2751215A1 publication Critical patent/CA2751215A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03049—Channel-conductance-controlling ATPase (3.6.3.49)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/382—Cystic fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2751215A 2009-02-02 2010-02-01 Cell lines expressing cftr and methods of using them Abandoned CA2751215A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14931209P 2009-02-02 2009-02-02
US61/149,312 2009-02-02
PCT/US2010/022778 WO2010088630A2 (en) 2009-02-02 2010-02-01 Cell lines expressing cftr and methods of using them

Publications (1)

Publication Number Publication Date
CA2751215A1 true CA2751215A1 (en) 2010-08-05

Family

ID=42396394

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2751215A Abandoned CA2751215A1 (en) 2009-02-02 2010-02-01 Cell lines expressing cftr and methods of using them

Country Status (6)

Country Link
US (2) US20120058918A1 (https=)
EP (1) EP2393930A4 (https=)
JP (1) JP2012516686A (https=)
CA (1) CA2751215A1 (https=)
MX (1) MX2011008131A (https=)
WO (1) WO2010088630A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297674A1 (en) * 2008-01-22 2010-11-25 Chromocell Corporation NOVEL CELL LINES EXPRESSING NaV AND METHODS USING THEM
EP2245171A2 (en) * 2008-02-01 2010-11-03 Chromocell Corporation Cell lines and methods for making and using them
EP2460006A2 (en) 2009-07-31 2012-06-06 Chromocell Corporation Methods and compositions for identifying and validating modulators of cell fate
US20120302573A1 (en) * 2011-05-25 2012-11-29 Paul Francis Jackson Methods of inhibiting pro matrix metalloproteinase activation
US20130014288A1 (en) * 2011-06-06 2013-01-10 Carnegie Mellon University Novel reporter-tagged recombinant membrane proteins with transmembrane linkers
FR2999191B1 (fr) * 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
US20190154661A1 (en) * 2016-05-09 2019-05-23 Proteostasis Therapeutics, Inc. Methods of identifying cftr modulators
EP3684463B1 (en) 2017-09-19 2025-05-14 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CN113382683A (zh) 2018-09-14 2021-09-10 纽罗因恒思蒙特实验有限责任公司 改善睡眠的系统和方法
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CN111910008B (zh) * 2020-08-21 2022-05-31 云南农业大学 一种鸡生长发育相关的分子标记及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164782A1 (en) * 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
WO2001003722A1 (en) * 1999-07-09 2001-01-18 Mayo Foundation For Medical Education And Research Cftr polypeptides, fragments thereof and methods of use to overcome biosynthetic misprocessing
WO2004020596A2 (en) * 2002-08-30 2004-03-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Polypeptides for increasing mutant cftr channel activity
CA2569402A1 (en) * 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
CA2600869A1 (en) * 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
NZ561925A (en) * 2005-04-13 2010-04-30 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
CA2653052A1 (en) * 2006-05-19 2007-11-29 The Scripps Research Institute Treatment of protein misfolding
DK2141985T3 (en) * 2007-03-28 2019-02-04 Univ Iowa Res Found Transgenetic pig model of cystic fibrosis

Also Published As

Publication number Publication date
US20120058918A1 (en) 2012-03-08
WO2010088630A2 (en) 2010-08-05
JP2012516686A (ja) 2012-07-26
WO2010088630A3 (en) 2010-11-25
EP2393930A4 (en) 2012-08-15
MX2011008131A (es) 2012-01-20
US20150315554A1 (en) 2015-11-05
EP2393930A2 (en) 2011-12-14

Similar Documents

Publication Publication Date Title
US20150315554A1 (en) Cell lines expressing cftr and methods of using them
EP2391647B1 (en) Cell lines expressing nav and methods of using them
CN103525751B (zh) 细胞系以及制备和使用其的方法
Boeckers et al. C‐terminal synaptic targeting elements for postsynaptic density proteins ProSAP1/Shank2 and ProSAP2/Shank3
US8097422B2 (en) Kir channel modulators
Piters et al. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function
EP2622351B1 (en) Neuropeptide q as modulator of gpcr galr2 and uses thereof
Wang et al. Functional evaluation of a novel GRIN2B missense variant associated with epilepsy and intellectual disability
Du et al. Functional characterization of novel NPRL3 mutations identified in three families with focal epilepsy
Yoshinaga et al. Dysregulation of N-terminal acetylation causes cardiac arrhythmia and cardiomyopathy
US20120028278A1 (en) Cell lines expressing guanylate cyclase-c and methods of using them
EP1982189A2 (en) Compositions and methods for high throughput screening of pharmacological chaperones
Pastore et al. Autism-associated PTCHD1 missense variants bind to the SNARE-associated protein SNAPIN but exhibit impaired subcellular trafficking
Lv et al. Regulation of Hedgehog Signaling Through Arih2-Mediated Smoothened Ubiquitination and Endoplasmic Reticulum-Associated Degradation
Shaikh Control of cellular trafficking of mammalian voltage sensitive phosphatase (VSP) through protein-protein interactions
Stockmann Functional analysis of microtubule-associated proteins and their effect on microtubule dynamics using advanced microscopy techniques
Merillon et al. Biallelic WDR91 variants cause a neurodevelopmental disorder through impaired endosomal maturation and autophagy dysregulation
Plach Serotonin 5-HT2A-Dopamine D2 Receptor Heterodimers: Characterization and Functional Evaluation
HK1152321B (en) Cell lines expressing gabaa and methods of using them
Powlowski Exploring Voltage-Gated Sodium Channel NaV1. 6 as an Interacting Partner with G Protein-Coupled Receptors
HK1167875A (en) Novel cell lines and methods

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150130

FZDE Discontinued

Effective date: 20200121